XP 21279

Drug Profile

XP 21279

Alternative Names: 279/CD; Levodopa prodrug - Arbor Pharmaceuticals; XP-21279; XP21279/carbidopa

Latest Information Update: 17 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XenoPort
  • Developer Arbor Pharmaceuticals
  • Class Antiparkinsonians; Catecholamines
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 30 Jun 2015 Phase II development is ongoing in USA
  • 30 Jun 2015 XenoPort is still considering partnering opportunities for the development and commercialisation of XP 21279 outside USA. http://www.xenoport.com/
  • 24 Apr 2013 XenoPort is considering partnering opportunities for the development and commercialisation of XP 21279 outside USA. http://www.xenoport.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top